id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1975-N-0336-0037,FDA,FDA-1975-N-0336,"Supplement from PBM Pharmaceuticals, Inc. (Buchanan Ingersoll & Rooney PC)",Other,Supplement (SUP),2012-11-02T04:00:00Z,2012,11,2012-11-02T04:00:00Z,,2017-12-05T21:55:01Z,,0,0,090000648115a3fb
FDA-1975-N-0336-0036,FDA,FDA-1975-N-0336,"Supplemental Information from PBM Pharmaceuticals, Inc. (Buchanan Ingersoll & Rooney PC) (Vol. 141-C)",Other,Supplement (SUP),2012-10-05T04:00:00Z,2012,10,2012-10-05T04:00:00Z,,2017-12-05T21:46:35Z,,0,0,0900006481136b5a
FDA-1975-N-0336-0035,FDA,FDA-1975-N-0336,Letter from Valeant Pharmaceuticals North America LLC to FDA/CDER,Other,Letter(s),2012-10-02T04:00:00Z,2012,10,2012-10-02T04:00:00Z,,2017-12-06T15:35:36Z,,0,0,09000064810f8657
FDA-1975-N-0336-0033,FDA,FDA-1975-N-0336,Memorandum of Telecon Between Pfizer Inc. and FDA/CDER,Other,Memorandum,2012-08-30T04:00:00Z,2012,8,2012-08-30T04:00:00Z,,2012-08-30T22:19:51Z,,0,0,0900006480f2629f
FDA-1975-N-0336-0034,FDA,FDA-1975-N-0336,FDA/CDER to Buchanan Ingersoli & Rooney PC - Letter,Other,Letter(s),2012-08-30T04:00:00Z,2012,8,2012-08-30T04:00:00Z,,2012-08-30T22:20:59Z,,0,0,09000064810c97ea
FDA-1975-N-0336-0032,FDA,FDA-1975-N-0336,Drugs for Human Use; Drug Efficacy Study Implementation: Certain Prescription Drugs Offered for Various Indications; Opportunity to Affirm Outstanding Hearing Request,Notice,General Notice,2012-07-24T04:00:00Z,2012,7,2012-07-24T04:00:00Z,,2017-12-06T15:53:40Z,2012-18015,0,0,09000064810ac248